Glenmark Secures ANDA Nod for Colesevelam HCL Tab | CORPORATE ETHOS

Glenmark Secures ANDA Nod for Colesevelam HCL Tab

By: | May 21, 2018

May 21: Mumbai-based drug maker Glenmark Pharmaceuticals Ltd on Wednesday said that its US division Glenmark Pharmaceuticals Inc., USA has been granted final approval by the United States Food & Drug Administration (USFDA) for its Colesevelam Hydrochloride Tablets, 625 mg, the generic version of Welchol Tablets, 625 mg, of Daiichi Sankyo Inc. The company has already commenced supplies of the product to the US market, it said.

According to IQVIATM sales data for the 12 month period ending March 2018, the Welchol Tablets, 625 mg market achieved annual sales of approximately $519.9 million.

Glenmark’s current portfolio consists of 135 products authorized for distribution in the US marketplace and 62 ANDA’s pending approval with the USFDA.

Glenmark shares were trading at Rs 505.45, up 0.56% from the previous closing of Rs 502.65, on BSE at 10.54 am today.